Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06550804 · ClinicalTrials.gov registry record · Phase 3
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
A Phase 3 study of HIV Infections and Adherence, Medication, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 126
- Enrollment target
- 1
- Study location
NCT06550804 is a Phase 3 study of HIV Infections and Adherence, Medication that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 126 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06550804, a Phase 3 study of HIV Infections and Adherence, Medication, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose using an electronic adherence device that is basically a pill container that can alert when it is not opened at a scheduled time. The investigators will use this device to alert the medication user at the time when medication is supposed to be taken if the device did not get opened and a pre-identified social support person or case manager when 2 or 7 consecutive days of nonadherence are detected, respectively. The investigators call our approach "A-Team" (Antiretroviral Therapy Electronic Adherence Monitoring). The aims of this application are to determine the acceptability and feasibility of real-time adherence monitoring in support persons and case managers of African American Men who have sex with Men and to test this approach for these men in a 6-month randomized controlled trial among 54 of these men living with HIV and measure ART adherence and viral suppression (the primary outcome).
Conditions Studied
Interventions
- BEHAVIORAL A-TEAM
Study Locations (1)
Illinois
- University of Illinois Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2026-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06550804
The ClinicalTrials.gov registry entry for NCT06550804 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (72% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which A-TEAM is the first listed.
NCT06550804 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06550804 about?
NCT06550804 is a clinical study titled "Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention". The investigators propose using an electronic adherence device that is basically a pill container that can alert when it is not opened at a scheduled time. The investigators will use this device to alert the medication user at the time when medication is supposed to be taken if the device did not ge...
What is the current status of trial NCT06550804?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 126 participants. The study started on 2024-10-01. Estimated completion is 2026-07.
What conditions does trial NCT06550804 study?
This clinical trial studies the following conditions: HIV Infections, Adherence, Medication.
What interventions are being tested in trial NCT06550804?
The interventions under investigation include: A-TEAM (BEHAVIORAL).
Who is sponsoring clinical trial NCT06550804?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06550804 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.